NASDAQ : HELP
Cybin Inc. — Key statistics
Healthcare · Biotechnology · Canada
Last price 10.71 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 782.47M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 658.27M |
| Enterprise Value | 491.91M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 73.06M |
| Shares Outstanding | 73.06M |
| Shares Change (YoY) | +103.06% |
| Shares Change (QoQ) | +4.63% |
| Owned by Insiders (%) | 15.21% |
| Owned by Institutions (%) | 39.00% |
| Float | 58.10M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.71 |
| P/TBV Ratio | 4.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.97 |
| Quick Ratio | 9.76 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -86.94% |
| Return on Assets (ROA) | -44.38% |
| Return on Invested Capital (ROIC) | -47.63% |
| Return on Capital Employed (ROCE) | -69.00% |
| Weighted Average Cost of Capital (WACC) | 7.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.71M |
| Employee Count | 100 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +19.56% |
| 50-Day Moving Average | 11.88 |
| 200-Day Moving Average | 7.72 |
| Relative Strength Index (RSI) | 31.23 |
| Average Volume (20 Days) | 1,543,545 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.01M |
| Short Previous Month | 3.46M |
| Short % of Shares Out | 4.12% |
| Short % of Float | 5.18% |
| Short Ratio (days to cover) | 1.71 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -167.05M |
| Pretax Income | -171.20M |
| Net Income | -171.20M |
| EBITDA | -166.94M |
| EBIT | -167.05M |
| Earnings Per Share (EPS) | -$4.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 166.37M |
| Total Debt | n/a |
| Net Cash | 166.37M |
| Net Cash Per Share | $2.28 |
| Equity (Book Value) | 242.09M |
| Book Value Per Share | 3.91 |
| Working Capital | 175.13M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -140.79M |
| Capital Expenditures | 34,000 |
| Depreciation & Amortization | 109,000 |
| Net Borrowing | -20.15M |
| Free Cash Flow | -140.76M |
| FCF Per Share | -$1.93 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -103.06% |
| Shareholder Yield | -103.06% |
| Earnings Yield | -44.94% |
| FCF Yield | -18.18% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $41.56 |
| Price Target Difference | 361.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 19, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:38 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |